The stock of Gritstone Bio Inc (GRTS) has seen a -7.55% decrease in the past week, with a -9.28% drop in the past month, and a -72.82% decrease in the past quarter. The volatility ratio for the week is 6.83%, and the volatility levels for the past 30 days are at 6.64% for GRTS. The simple moving average for the last 20 days is -4.63% for GRTS stock, with a simple moving average of -56.69% for the last 200 days.
Is It Worth Investing in Gritstone Bio Inc (NASDAQ: GRTS) Right Now?
Additionally, the 36-month beta value for GRTS is 0.53. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for GRTS is 99.64M and currently, short sellers hold a 11.64% ratio of that float. The average trading volume of GRTS on June 20, 2024 was 2.82M shares.
GRTS) stock’s latest price update
The stock price of Gritstone Bio Inc (NASDAQ: GRTS) has plunged by -4.30 when compared to previous closing price of 0.78, but the company has seen a -7.55% decline in its stock price over the last five trading sessions. accesswire.com reported 2024-06-20 that The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gritstone bio, Inc. (“Gritstone” or “the Company”) (NASDAQ:GRTS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company’s securities between March 9, 2023 and February 29, 2024, inclusive (the “Class Period”), are encouraged to contact the firm before August 6, 2024.
Analysts’ Opinion of GRTS
Many brokerage firms have already submitted their reports for GRTS stocks, with JMP Securities repeating the rating for GRTS by listing it as a “Mkt Outperform.” The predicted price for GRTS in the upcoming period, according to JMP Securities is $4 based on the research report published on February 28, 2024 of the current year 2024.
B. Riley Securities gave a rating of “Buy” to GRTS, setting the target price at $8 in the report published on March 28th of the previous year.
GRTS Trading at -8.44% from the 50-Day Moving Average
After a stumble in the market that brought GRTS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.72% of loss for the given period.
Volatility was left at 6.64%, however, over the last 30 days, the volatility rate increased by 6.83%, as shares sank -10.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.96% lower at present.
During the last 5 trading sessions, GRTS fell by -7.28%, which changed the moving average for the period of 200-days by -59.33% in comparison to the 20-day moving average, which settled at $0.7738. In addition, Gritstone Bio Inc saw -63.63% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GRTS starting from Allen Andrew R, who sale 24,263 shares at the price of $0.75 back on May 16 ’24. After this action, Allen Andrew R now owns 985,360 shares of Gritstone Bio Inc, valued at $18,156 using the latest closing price.
Jones Erin, the EVP, CHIEF OPERATING OFFICER of Gritstone Bio Inc, sale 13,749 shares at $0.75 during a trade that took place back on May 16 ’24, which means that Jones Erin is holding 359,293 shares at $10,288 based on the most recent closing price.
Stock Fundamentals for GRTS
Current profitability levels for the company are sitting at:
- -76.68 for the present operating margin
- -2.55 for the gross margin
The net margin for Gritstone Bio Inc stands at -70.92. The total capital return value is set at -1.41. Equity return is now at value -187.15, with -83.47 for asset returns.
Based on Gritstone Bio Inc (GRTS), the company’s capital structure generated 0.77 points at debt to capital in total, while cash flow to debt ratio is standing at -2.76. The debt to equity ratio resting at 3.38. The interest coverage ratio of the stock is -62.46.
Currently, EBITDA for the company is -147.04 million with net debt to EBITDA at -0.4. When we switch over and look at the enterprise to sales, we see a ratio of 69.45. The receivables turnover for the company is 9.92for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.99.
Conclusion
In conclusion, Gritstone Bio Inc (GRTS) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
